Melissa J Joliat

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine
    Melissa J Joliat
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychiatry 65:373-8. 2004
  2. ncbi request reprint Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study
    Stephan A Chalon
    Lilly Research Laboratories, Mont Saint Guibert, Belgium
    Neuropsychopharmacology 28:1685-93. 2003
  3. ncbi request reprint Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents
    Mary Nilsson
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Child Adolesc Psychopharmacol 14:412-7. 2004
  4. ncbi request reprint Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine
    Melissa J Joliat
    J Clin Psychopharmacol 24:464-7. 2004
  5. ncbi request reprint Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment
    Teri Pearlstein
    Women s Behavioral Health Program, Women and Infants Hospital, Providence, RI 02905 2499, USA
    Am J Obstet Gynecol 188:887-95. 2003

Detail Information

Publications5

  1. ncbi request reprint Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine
    Melissa J Joliat
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Psychiatry 65:373-8. 2004
    ..We report a retrospective pooled analysis of 2 studies to assess the effect of associated anxiety on the efficacy of fluoxetine in the continuation treatment phase of MDD...
  2. ncbi request reprint Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study
    Stephan A Chalon
    Lilly Research Laboratories, Mont Saint Guibert, Belgium
    Neuropsychopharmacology 28:1685-93. 2003
    ..The lack of a detectable impact of duloxetine on TYR PD30 suggests that this may not be the most sensitive indirect measure of NE reuptake when assessing dual reuptake inhibitors...
  3. ncbi request reprint Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents
    Mary Nilsson
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Child Adolesc Psychopharmacol 14:412-7. 2004
    ..The aim of this study was to assess the safety of subchronic fluoxetine treatment for major depressive disorder (MDD) in children and adolescents...
  4. ncbi request reprint Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine
    Melissa J Joliat
    J Clin Psychopharmacol 24:464-7. 2004
  5. ncbi request reprint Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment
    Teri Pearlstein
    Women s Behavioral Health Program, Women and Infants Hospital, Providence, RI 02905 2499, USA
    Am J Obstet Gynecol 188:887-95. 2003
    ..The aim of this study was to use the data from two clinical trials to evaluate premenstrual dysphoric disorder symptom severity after the discontinuation of fluoxetine treatment...